Mobile app version of munafa.org
Login or Join
 Learn then Earn
stockMarketNEWS

 story : Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's disease psychosis #FinanceUSA #StockMarketNEWS Acadia Pharmaceuticals Inc. said

@stockMarketNEWS 9 Days ago

Posted in: #FinanceUSA #StockMarketNEWS

Acadia Pharmaceuticals stock halted for FDA panel to review treatment for hallucinations stemming from Alzheimer's disease psychosis #FinanceUSA #StockMarketNEWS
Acadia Pharmaceuticals Inc. said Friday its stock will be halted from trading Friday as a U.S. Food and Drug Administration panel meets virtually to discuss a new drug application for a treatment for hallucinations and delusions associated with Alzheimer's disease psychosis. The FDA's Psychopharmacologic Drugs Advisory Committee will review Acadia's Nuplazid at a meeting scheduled for 8:45 a.m. Eastern. About six million people living in the U.S. have Alzheimer's disease, according to the Alzheimer's Association and about 30% of those suffer from psychosis. Acadia shares have fallen 16% in the year to date, while the S&P 500 has fallen 23%.


Munafa USA Munafa India Munafa NSE


Report

Login to follow story

More posts by @stockMarketNEWS

Munafa ebook, learn stock market trading

0 Comments

Sorted by latest first Latest Oldest Best

Daily analysis, news, Munafa stocks list in email:

Back to top | Use Dark Theme